Harry Aaldenberg
Keine laufenden Positionen mehr
Ursprung des Netzwerks ersten Grades von Harry Aaldenberg
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
MUbio Holding BV
 MUbio Holding BV BiotechnologyHealth Technology MUbio Products B.V. (MUbio) is a privately owned Dutch biotech company, founded in 2000 by Dr. R. Vleugels and Prof. Dr. F. Ramaekers. The company originated as a spin out from the Department of Molecular Cell Biology of the Maastricht University. MUbio produces high quality reagents and bioassays for cell biology and biomedical research. MUbio's product portfolio includes an increasing number of well-characterized antibodies for oncology research, produced in an ISO certified laboratory. MUbio’s partnered and proprietary R&D projects focus on the identification and validation of cancer biomarkers, development of lung cancer diagnostic kits & research and development of a lung cancer vaccine.
5
| Extinct | Biotechnology | 5 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Harry Aaldenberg
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| JOHNSON & JOHNSON | Pharmaceuticals: Major | Corporate Officer/Principal | |
| TIGENIX NV | Medical Specialties | Director/Board Member Public Communications Contact | |
| Maastricht University | College/University | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
Ernst & Young LLP (Missouri)
 Ernst & Young LLP (Missouri) Miscellaneous Commercial ServicesCommercial Services Ernst & Young provides accounting services. Its services include auditing, accounting, tax and transaction services, assurance and advisory business, online transaction advisory and a wide range of financial services. The company was founded by Arthur Young and Alwin C. Ernst in 1881 and is headquartered in Kansas City, MO. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Limburgse Reconversie Maatschappij NV
 Limburgse Reconversie Maatschappij NV Investment ManagersFinance Limburgse Reconversie Maatschappij NV (LRM) is an independent private equity firm which was founded in 1994 by the Flemish government. Limburgse Reconversie Maatschappij NV is headquartered in Hasselt, Beglium. | Investment Managers | Private Equity Investor | |
| Erasmus University Rotterdam | College/University | Masters Business Admin | |
| University of Leiden | College/University | Graduate Degree | |
| Ghent University | College/University | Doctorate Degree | |
| Radboud University Nijmegen | College/University | Doctorate Degree | |
| Hasselt University | College/University | Graduate Degree Doctorate Degree | |
| University Medical Center of Utrecht | College/University | Doctorate Degree | |
Apitope International NV
 Apitope International NV BiotechnologyHealth Technology Apitope International NV develops therapeutic vaccines. It operates as a bio-pharmaceutical company that engages in developing peptide therapies. The firm specializes on the discovery and development of revolutionary disease modifying therapies for treating autoimmune and allergic diseases, including multiple sclerosis, and Graves’ disease, FVIII intolerance and uveitis. The company was founded by David Wraith in 2002 and is headquartered in Diepenbeek, Belgium. | Biotechnology | Director/Board Member | |
Apitope Technology (Bristol) Ltd.
 Apitope Technology (Bristol) Ltd. Miscellaneous Commercial ServicesCommercial Services Apitope Technology (Bristol) Ltd. is a European biotech company developing therapeutic vaccines for treating autoimmune and allergic diseases, including multiple sclerosis, Type 1 diabetes, Graves' disease, allergies and organ transplant rejection. The team at Apitope is developing potential therapies intended to selectively treat the underlying cause of a range of autoimmune diseases rather than simply treat the disease symptoms or non-specifically suppress the whole immune system. Apitope's approach is based on well-established scientific evidence published in leading scientific journals showing that soluble, synthetic peptides can selectively suppress abnormal immune responses and reinstate the normal immune balance and thereby, tolerance. The firm's strategy is to position itself as a significant player in the therapeutic peptide space and make it a partner of choice for pharmaceutical companies keen to develop disease modifiers for autoimmune conditions. It has a highly experienced senior management team, with a proven track record in discovering and developing innovative compounds. The company's lead product candidate is under investigation for the potential treatment of multiple sclerosis and is currently in Phase I clinical development. It is partnered with Merck-Serono (a division of Merck KGaA, Darmstadt, Germany), one of the leading companies in the development and marketing of MS therapies. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
SEPS Pharma NV
 SEPS Pharma NV Pharmaceuticals: GenericHealth Technology SEPS Pharma NV provides controlled drug delivery and develops self emulsifying pro drug systems. Its services include preformulation, formulation development and analytical development. The company was founded on October 19, 2007 and is headquartered in Diepenbeek, Belgium. | Pharmaceuticals: Generic | Director/Board Member Director/Board Member | |
| Life Sciences Consultancy | Founder | ||
| NovoVacs BV | Founder | ||
| Dutch Vaccines Group | Director/Board Member | ||
Life Sciences Development Campus NV
 Life Sciences Development Campus NV Miscellaneous Commercial ServicesCommercial Services Life Sciences Development Campus NV provides research and development services in the field of biomedical life sciences. The company is headquartered in Abis, BelGium. | Miscellaneous Commercial Services | Director/Board Member Chief Executive Officer | |
V&V Invest BV /BE/
 V&V Invest BV /BE/ Real Estate DevelopmentFinance V&V Invest BV is a residential construction company based in Hasselt, Belgium. and has subsidiaries in Belgium. The Belgian company specializes in developing residential construction projects. | Real Estate Development | Director/Board Member | |
Amgen BV
 Amgen BV Pharmaceuticals: MajorHealth Technology Part of Amgen, Inc., Amgen BV is a Dutch biotech company that specializes in using living cells to create biologic medicines. The company has helped pioneer the biotech industry and are committed to discovering, developing, manufacturing, and delivering innovative human therapeutics to patients suffering from serious illnesses. Amgen's medicines treat serious illnesses and typically address diseases with a limited number of treatment options. The company has a presence in approximately 100 countries and have reached millions of people with their products. Amgen has a robust pipeline focused on the pursuit of transformative medicines with large effects in serious diseases, using human genetic validation whenever possible to strengthen the evidence base for as many of their programs as possible. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| Hogeschool-Universiteit Brussel | College/University | Graduate Degree | |
Amakem NV
 Amakem NV Medical/Nursing ServicesHealth Services Amakem NV operates as a biopharmaceutical company. It uses kinase inhibitors for treatments of bowel, eye, and lung diseases. The company was founded by Jack Elands, Dirk Leysen, Olivier Raynald Defert, and Nadya Kaval on July 22, 2009 and is headquartered in Diepenbeek, Belgium. | Medical/Nursing Services | Director/Board Member | |
| Nexins Research BV | Director/Board Member | ||
| The Federation of European Societies of Plant Biology | Director/Board Member | ||
| European Cytoskeleton Forum | Corporate Secretary | ||
| Dutch Society for Cell Biology | President | ||
| LifetecZONe | Director/Board Member | ||
Fast Forward Pharmaceuticals BV
 Fast Forward Pharmaceuticals BV Medical SpecialtiesHealth Technology Fast Forward Pharmaceuticals BV develops novel disease-modifying therapeutics for the treatment of inflammatory and autoimmune diseases. It is developing an anti-CD40 monoclonal antibody therapy for the treatment of chronic inflammatory diseases like primary biliary cirrhosis and Crohn’s disease. The company was founded by Louis Boon in October 2010 and is headquartered in Utrecht, Netherlands. | Medical Specialties | Director/Board Member | |
| MINERVA NEUROSCIENCES, INC. | Pharmaceuticals: Major | Director/Board Member | |
Medinvents NV
 Medinvents NV Medical SpecialtiesHealth Technology Medinvents NV engages in the manufacture of biopsy surgical instruments. The company was founded on December 28, 1992 and is headquartered in Hasselt, Belgium. | Medical Specialties | Director/Board Member | |
| Andaz Partners | Corporate Officer/Principal | ||
| Cube Management Co. | Corporate Officer/Principal |
Statistik
International
| Belgien | 15 |
| Niederlande | 14 |
| Vereinigte Staaten | 5 |
| Vereinigtes Königreich | 3 |
| Spanien | 2 |
Sektoral
| Health Technology | 10 |
| Consumer Services | 9 |
| Commercial Services | 4 |
| Finance | 4 |
| Distribution Services | 2 |
Operativ
| Director/Board Member | 20 |
| Corporate Officer/Principal | 8 |
| Founder | 4 |
| Doctorate Degree | 4 |
| Graduate Degree | 3 |
Am stärksten vernetzte Beziehungen
- Börse
- Insiders
- Harry Aaldenberg
- Unternehmensverbindungen
